Aquestive Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 5, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 5, 2025
AQST$3.52-0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows for the Years Ended
Statements of Cash Flows (In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(44,137) | $(7,870) |
| Adjustments to reconcile net loss to net cash used for operating activities: | ||
| Depreciation, amortization, and impairment | 718 | 1,345 |
| Share-based compensation | 7,099 | 2,689 |
| Amortization of debt issuance costs and discounts | 10,714 | 1,972 |
| Gain on contract termination | (300) | — |
| Loss on the extinguishment of debt | — | 1,029 |
| Other, net | 104 | (204) |
| Changes in operating assets and liabilities: | ||
| Trade receivables and other receivables, net | 1,094 | (3,073) |
| Inventories | 725 | (989) |
| Prepaid expenses and other assets | (223) | 1,290 |
| Accounts payable | 2,782 | (1,020) |
| Accrued expenses and other liabilities | (1,492) | (2,515) |
| Deferred revenue | (12,843) | 966 |
| Net cash used for operating activities | (35,759) | (6,380) |
| Cash flows from investing activities: | ||
| Capital expenditures | (159) | (995) |
| Net cash used for investing activities | (159) | (995) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock under public equity offering-ATM, net | 11,783 | 8,912 |
| Proceeds from common stock issued under public equity offering, net | 71,974 | — |
| Proceeds from exercise of warrants, net | 165 | 8,307 |
| Proceeds from shares issued under employee stock purchase plan | 67 | 39 |
| Proceeds from exercise of stock options | 732 | 1 |
| Proceeds from issuance of debt | — | 31,144 |
| Proceeds from issuance of Royalty Rights Agreements | — | 13,856 |
| Repayment of debt principal including lease liabilities | (23) | (51,529) |
| Payments for royalty obligations | (5) | — |
| Payments for financing costs | — | (4,643) |
| Premium paid to retire debt | — | (2,102) |
| Payments for taxes on share-based compensation | (1,101) | (11) |
| Net cash provided by financing activities | 83,592 | 3,974 |
| Net increase (decrease) in cash and cash equivalents | 47,674 | (3,401) |
| Cash and cash equivalents: | ||
| Beginning of period | 23,872 | 27,273 |
| End of period | $71,546 | $23,872 |
| Supplemental disclosures of cash flow information: | ||
| Cash payments for interest | $7,097 | $4,602 |
| Cash payments for income taxes | $305 | $— |
| Non-cash investing activities: capital expenditures in accounts payable | $78 | $— |
| Non-cash financing activities: accrued taxes on share-based compensation | $250 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.